What’s happening in neuro device investing? In a new SVB sub-sector report we cover the private companies that are developing devices to treat neurological diseases, as well as non-neuro diseases in which the therapeutic effect is mediated through the nervous system.
Key insights from the report:
- Financings increased by over 40 percent and invested equity grew by over 50 percent from 2016 to 2017.
- Nervous system diseases — including pain, epilepsy and movement disorders, among others — represented the largest disease focus for neuro devices, capturing 40-45 percent of financings in both 2016 and 2017.
- Significant early-stage investment took place, with 16 Seed and Series A financings raising more than $10 million each.